RARE vs. BHVN, HCM, PBH, ARWR, IDYA, INSM, SMMT, AXSM, CORT, and PTCT
Should you be buying Ultragenyx Pharmaceutical stock or one of its competitors? The main competitors of Ultragenyx Pharmaceutical include Biohaven (BHVN), HUTCHMED (HCM), Prestige Consumer Healthcare (PBH), Arrowhead Pharmaceuticals (ARWR), IDEAYA Biosciences (IDYA), Insmed (INSM), Summit Therapeutics (SMMT), Axsome Therapeutics (AXSM), Corcept Therapeutics (CORT), and PTC Therapeutics (PTCT). These companies are all part of the "pharmaceutical preparations" industry.
Biohaven (NYSE:BHVN) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, earnings, profitability, media sentiment, valuation, risk and community ranking.
Biohaven presently has a consensus price target of $51.63, suggesting a potential upside of 32.75%. Ultragenyx Pharmaceutical has a consensus price target of $87.85, suggesting a potential upside of 121.22%. Given Biohaven's higher probable upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Biohaven.
Biohaven has a beta of 1.26, meaning that its share price is 26% more volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500.
Biohaven has higher revenue and earnings than Ultragenyx Pharmaceutical. Biohaven is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Ultragenyx Pharmaceutical received 434 more outperform votes than Biohaven when rated by MarketBeat users. Likewise, 77.11% of users gave Ultragenyx Pharmaceutical an outperform vote while only 65.43% of users gave Biohaven an outperform vote.
88.8% of Biohaven shares are owned by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 16.0% of Biohaven shares are owned by company insiders. Comparatively, 5.8% of Ultragenyx Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
In the previous week, Ultragenyx Pharmaceutical had 6 more articles in the media than Biohaven. MarketBeat recorded 7 mentions for Ultragenyx Pharmaceutical and 1 mentions for Biohaven. Ultragenyx Pharmaceutical's average media sentiment score of 1.41 beat Biohaven's score of 1.01 indicating that Biohaven is being referred to more favorably in the media.
Biohaven has a net margin of 0.00% compared to Biohaven's net margin of -138.58%. Ultragenyx Pharmaceutical's return on equity of -147.06% beat Biohaven's return on equity.
Summary
Biohaven and Ultragenyx Pharmaceutical tied by winning 9 of the 18 factors compared between the two stocks.
Get Ultragenyx Pharmaceutical News Delivered to You Automatically
Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ultragenyx Pharmaceutical Competitors List
Related Companies and Tools
